- Ideas
- Markets
- Cryptocurrencies
- Currencies
- Stocks
- Earnings Calendar
- Stock Screener
- Large-Cap
- Top Gainers
- Top Losers
- Most Active
- Most Volatile
- Overbought
- Oversold
- All Time High
- All Time Low
- Sector & Industry
Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc
- Indices
S&P 500, Nasdaq Composite, Dow 30, Nikkei 225, DAX Index, FTSE 100
- Futures
- Bonds
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
- CFDs
Gold, Brent Oil, Crude Oil, CFDs on Natural Gas, Palladium, Silver
- Scripts
- Oscillators
- Centered Oscillators
- Volatility
- Trend Analysis
- Volume
- Moving Average
- Exponential Moving Average (EMA)
- Weighted Moving Average (WMA)
- Simple Moving Average (SMA)
- Hull Moving Average (HMA)
- Kaufman's Adaptive Moving Average (KAMA)
- Smoothed Moving Average (SMMA)
- Variable Index Dynamic Average (VIDYA)
- Volume-weighted Moving Average (VWMA)
- Fractal Adaptive Moving Average (FRAMA)
- Double Exponential Moving Average (DEMA)
- Breadth Indicators
- Bill Williams Indicators
- Screener
- Shows
- Chart
- More
DENALI THERAPEUTICS INC
NASDAQ
DNLI
DNLI
DENALI THERAPEUTICS INC
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E
DNLI, 1D
Long
DNLI looking interesting as long setup. It broken down from a downward channel and now traded back to the channel formation like a bump and run formation. It has some insider buying and strong moneyflow. We think it has good upside potential from current level.
2
DNLI, 1D
Pulled right back to the 61.8% fib retracement and bounced after massive month. Common pattern
2
Valuation
Enterprise Value/EBITDA, TTM
—
Enterprise Value, FQ
—
Market Cap — Basic
—
Number of Employees
—
Number of Shareholders
—
Price/Earnings, TTM
—
Price/Revenue, TTM
—
Price/Book Ratio, FY
—
Price/Sales Ratio, FY
—
Balance Sheet
Current Ratio, FQ
—
Debt to Equity, FQ
—
Net Debt, FQ
—
Quick Ratio, FQ
—
Total Assets, FQ
—
Total Debt, FQ
—
Operating Metrics
Return on Assets, TTM
—
Return on Equity, TTM
—
Return on Invested Capital, TTM
—
Revenue per Employee, TTM
—
Price History
Average Volume (10 day)
—
Beta - 1 Year
—
Price - 52 Week High
—
Price - 52 Week Low
—
Dividends
Dividends Paid, FY
—
Dividends per Share, FY
—
Expected Annual Dividends
—
Dividends Yield
—
Margins
Net Margin, TTM
—
Gross Margin, TTM
—
Operating Margin, TTM
—
Pretax Margin, TTM
—
Income Statement
Basic EPS, Net Income
—
Earnings per Share, Basic, TTM
—
EBITDA, TTM
—
Gross Profit, FY
—
Last Annual EPS
—
Last Annual Revenue, FY
—
Net Income, FY
—
Total Revenue, FY
—
Free Cash Flow, TTM
—
Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 230
Denali Therapeutics Inc. is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately four specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration. The Company’s development programs include Lysosomal Function Pathway, Glial Biology Pathway, and Cellular Homeostasis Pathway. Its product pipeline includes drug candidates such as DNL201, DNL 151, ATV:aSyn, ETV:IDS, DNL747, and ATV:TREM2.
News
Community & Tools
For Business
© 2019 TradingView
Stock Charts & Forex Charts
Stock Charts & Forex Charts
Made with
From the creators of MultiCharts
Select market data provided by ICE Data Services